Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 4/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12741978 | 0.87 | PTGER2 (0.39) | PTGER2TSHRHTTSMN1; SMN2ALOX5 | |
| SCHEMBL12810016 | 0.87 | ALOX5 (0.41) | PTGER2TSHRHTTSMN1; SMN2ALOX5 | |
| SCHEMBL6916806 | 0.84 | PTGER2 (0.35) | PTGER2PRKCATSHRHTTSMN1; SMN2 | |
| SCHEMBL2793920 | 0.84 | PTGER2 (0.35) | PTGER2PRKCATSHRHTTSMN1; SMN2 | |
| SCHEMBL12014043 | 0.78 | BRD4 (0.34) | TSHRBRD4 | |
| SCHEMBL15526611 | 0.78 | PRKCA (0.34) | PTGER2PRKCATSHRHTTSMN1; SMN2 | |
| SCHEMBL18019136 | 0.78 | KDM5A (0.36) | PTGER2PRKCATSHRHTTSMN1; SMN2 | |
| SCHEMBL3938678 | 0.75 | ALOX5 (0.40) | PRKCATSHRHTTSMN1; SMN2ALOX5 | |
| SCHEMBL3935340 | 0.75 | ALOX5 (0.40) | PRKCATSHRHTTSMN1; SMN2ALOX5 | |
| SCHEMBL3935336 | 0.75 | ALOX5 (0.40) | PRKCATSHRHTTSMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461206-B2 | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin | L'OREAL (FR) | 2013-06-11 | — | — | US | disclosed |
| US-8461206-B2 | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin | L'OREAL (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20110085999-A9 | USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN | L'OREAL S.A. | 2011-04-14 | — | — | US | disclosed |
| US-20100015080-A1 | USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN | L'OREAL S.A. | 2010-01-21 | — | — | US | disclosed |
| US-7365097-B2 | Use of at least one (dihydro)jasmonic acid derivative as a desquamating agent | L'OREAL, S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085999-A9 | USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN | CUTA, ALOX15, ALOX15B | PTGER2 104/4885PRKCA 574/4885TSHR 4022/4885 |
| US-20100015080-A1 | USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN | CUTA, ALOX15, ALOX15B | PTGER2 104/4885PRKCA 574/4885TSHR 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.